AveXis, Inc. (NASDAQ:AVXS) Rating Reiterated by Goldman Sachs Group, Inc. (The)

Goldman Sachs Group, Inc. (The) reiterated their buy rating on shares of AveXis, Inc. (NASDAQ:AVXS) in a report issued on Friday, October 6th, MarketBeat reports. The brokerage currently has a $130.00 target price on the stock.

A number of other research firms have also weighed in on AVXS. BMO Capital Markets reissued a buy rating and issued a $123.00 target price on shares of AveXis in a research note on Friday, August 11th. Zacks Investment Research raised shares of AveXis from a sell rating to a hold rating in a research note on Thursday, July 13th. Morgan Stanley restated an overweight rating and set a $118.00 price target on shares of AveXis in a report on Wednesday, August 9th. Citigroup Inc. set a $100.00 price target on shares of AveXis and gave the stock a buy rating in a report on Thursday, June 15th. Finally, Wells Fargo & Company restated an outperform rating and set a $134.00 price target (up previously from $89.00) on shares of AveXis in a report on Tuesday, September 5th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the stock. AveXis presently has a consensus rating of Buy and an average target price of $107.38.

AveXis (NASDAQ AVXS) opened at 101.22 on Friday. The stock’s 50 day moving average price is $95.55 and its 200-day moving average price is $84.31. AveXis has a 12 month low of $43.06 and a 12 month high of $106.00. The stock’s market cap is $3.23 billion.

AveXis (NASDAQ:AVXS) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($1.10). During the same quarter in the previous year, the firm earned ($0.68) EPS. Analysts anticipate that AveXis will post ($6.22) EPS for the current fiscal year.

WARNING: “AveXis, Inc. (NASDAQ:AVXS) Rating Reiterated by Goldman Sachs Group, Inc. (The)” was first published by BBNS and is the property of of BBNS. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://baseballnewssource.com/markets/goldman-sachs-group-inc-the-reiterates-buy-rating-for-avexis-inc-avxs/1703003.html.

In other news, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $91.52, for a total transaction of $162,905.60. Following the completion of the sale, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $162,905.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction on Monday, October 9th. The stock was sold at an average price of $101.46, for a total transaction of $1,521,900.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,340 shares of company stock valued at $2,023,896. Insiders own 18.60% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC lifted its position in AveXis by 13.1% in the second quarter. FMR LLC now owns 4,705,433 shares of the company’s stock valued at $386,598,000 after acquiring an additional 544,475 shares during the last quarter. BlackRock Inc. lifted its position in AveXis by 34.7% in the second quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock valued at $189,069,000 after acquiring an additional 592,843 shares during the last quarter. Vanguard Group Inc. lifted its position in AveXis by 31.8% in the second quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock valued at $129,419,000 after acquiring an additional 380,396 shares during the last quarter. State Street Corp lifted its position in AveXis by 104.2% in the second quarter. State Street Corp now owns 1,000,001 shares of the company’s stock valued at $82,163,000 after acquiring an additional 510,189 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its position in AveXis by 32.8% in the first quarter. Point72 Asset Management L.P. now owns 717,514 shares of the company’s stock valued at $54,553,000 after acquiring an additional 177,114 shares during the last quarter. 94.71% of the stock is owned by institutional investors and hedge funds.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Alex Cora Becomes New Manager for Boston Red Sox
Alex Cora Becomes New Manager for Boston Red Sox
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends


Leave a Reply

 
© 2006-2017 BBNS.